Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Total Liabilities: 2023-2024

Historic Total Liabilities for Inhibrx Biosciences (INBX) over the last 2 years, with Dec 2024 value amounting to $47.2 million.

  • Inhibrx Biosciences' Total Liabilities rose 218.95% to $140.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $140.6 million, marking a year-over-year increase of 218.95%. This contributed to the annual value of $47.2 million for FY2024, which is 82.15% down from last year.
  • As of FY2024, Inhibrx Biosciences' Total Liabilities stood at $47.2 million, which was down 82.15% from $264.4 million recorded in FY2023.
  • In the past 5 years, Inhibrx Biosciences' Total Liabilities registered a high of $264.4 million during FY2023, and its lowest value of $47.2 million during FY2024.
  • Over the past 2 years, Inhibrx Biosciences' median Total Liabilities value was $155.8 million (recorded in 2023), while the average stood at $155.8 million.
  • Data for Inhibrx Biosciences' Total Liabilities shows a maximum YoY slumped of 82.15% (in 2024) over the last 5 years.
  • Inhibrx Biosciences' Total Liabilities (Yearly) stood at $264.4 million in 2023, then plummeted by 82.15% to $47.2 million in 2024.